Biography for Eric Palmer
Eric Palmer is a business and technology journalist with more than three decades of prize-winning experience as a reporter and editor with daily, weekly, monthly and online publications. He was heatlhcare reporter for The Kansas City Star before becoming deputy business editor for the daily newspaper. He spent eight years as editor of The Kansas City Business Journal, which had a strong emphasis on the healthcare industry. On the personal side, he is an avid fly fisherman, cooks and collects wine, and likes to travel with his family.
Articles by Eric Palmer
Australian judge kills Merck Vioxx class action settlement
A federal judge in Australia has put the kibosh on a half-million-dollar settlement over ill effects of Merck's ($MRK) painkiller Vioxx, a drug that has spawned billions of dollars in litigation.
Sanofi, France remain at odds over fate of 600 R&D jobs
Sanofi CEO Chris Viehbacher has reviled the company's research site in Toulouse, France as unproductive and overly costly. But try as he may, he can't seem to rid himself and the company of the center and its 612 researchers, a move Viehbacher initially advocated as part of 2,500 job reduction plan in the mother country.
India sets controversial price caps on 650 drugs
India has started the countdown on new price controls for a vastly expanded list of drugs, a move that is expected to cut deeply into the profits of drugmakers for hundreds of drugs.
EMA says Bayer's Diane-35 has more benefit than risk
France drug regulator in January yanked Bayer's contraceptive Diane-35 off the market and insisted the European Medicines Agency investigate its off-label use as an acne treatment and its risks of blood clots. The EMA has done that and has come down in support of the drug, even for the off-label use.
GSK tries novel approach in emerging markets: price cuts
GlaxoSmithKline CFO Simon Dingemans has found one of the mainstays of retail works just fine for drugs, particularly in emerging markets where GSK wants to build its foothold. You just put them on sale.
FDA gives Novartis' Ilaris big boost with nod for rare juvenile arthritis
Novartis has grabbed one of two new indications it was shooting for with its rare disease drug Ilaris, one step toward turning the drug into a blockbuster.
Dunsire out as Takeda rolls Millennium into its global R&D operations
CEO Deborah Dunsire is retiring from Millennium, the unit Takeda bought about 5 years ago, as Millennium's oncology R&D is rolled up into the parent company's global research organization.
AbbVie, Pfizer's Zoetis deals ignite enormous leap in M&A value
Pfizer's spinoff of its animal health business into Zoetis is the biggest IPO this year. And the spinoff that created the newest Big Pharma company, AbbVie, was no slouch.
Amgen forges Chinese JV for Vectibix
The China drug market is getting trickier but that is not stopping the big names of biotech and pharma from plowing ahead with tie-ups of various kinds to sell into the enormous market. Amgen today said it is ready to attack the Chinese market with one of its cancer drugs.
WSJ: J&J federal Risperdal deal hung up on language over breasts
Johnson & Johnson has been negotiating terms of a multibillion dollar settlement over aggressive marketing of its antipsychotic drug Risperdal with federal authorities for at least two years, and now it is hung on talk over breasts, The Wall Street Journal says.
